Cytotoxic effect of the VVGMCSF-Lact oncolytic virus against 3D cultures of human glioblastoma cells U-87 MG

Background. One of the promising methods of treating tumors is virotherapy, which is based on direct lysis of cancer cells by a virus and a virus-mediated antitumor immune response of the body. For the recombinant vaccinia virus strain VVGMCSF-Lact, producing human GMCSF and the oncotoxic protein lactaptin, cytotoxic and antitumor effects were shown in experiments in vitro and in vivo, respectively, when using adhesive cultures of U-87 MG human glioblastoma cells. 3D cultures are a more relevant tumor model than adhesive models, as they more fully reflect the realistic scenario of cancer development, as well as the response of the tumor to anticancer therapy.

The aim. To evaluate the cytotoxic effect of the oncolytic virus VV-GMCSF-Lact against 3D cultures of human glioblastoma U-87 MG.

Materials and methods. The following methods were used in the work: cultivation of 3D cell cultures, cytofluorometry, microscopic analysis, virus titration, statistical analysis.

Results. U-87 MG cells were transduced with a lentiviral vector carrying the GFP reporter gene. The cytotoxicity of the VV-GMCSF-Lact virus (IC50) against the studied cells was 0.024 PFU/cell. U-87 MG cells were cultured under conditions for the formation of 3D structures. Microscopic analysis showed the oncolytic effect of the virus on the cells of 3D cultures as early as 24 hours after the start of incubation. Flow cytometry showed an increase in the granularity of glioblastoma cells under the action of the virus, which indicates active replication of the virus in the cells. The virus titer was 0.44 PFU/cell.

Conclusions. The recombinant VV-GMCSF-Lact virus has a cytotoxic effect on 3D human glioblastoma U-87 MG cell cultures and actively replicates in them. In the future, to test the oncolytic effect of VV-GMCSF-Lact, it is planned to use not only 3D human glioblastoma cultures, but also cerebral organelles obtained in the process of cocultivation of glioblastoma cells and induced human pluripotent cells.

1. Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018; 54: 7-13. doi: 10.1016/j.jocn.2018.05.002

2. Koval O, Kochneva G, Tkachenko A, Troitskaya O, Sivolobova G, Grazhdantseva A, et al. Recombinant vaccinia viruses coding transgenes of apoptosis-inducing proteins enhance apoptosis but not immunogenicity of infected tumor cells. Biomed Res Int. 2017; 2017: 3620510. doi: 10.1155/2017/3620510

3. Vasileva N, Ageenko A, Dmitrieva M, Nushtaeva A, Mishinov S, Kochneva G, et al. Double recombinant vaccinia virus: A candidate drug against human glioblastoma. Life (Basel). 2021; 11(10): 1084. doi: 10.3390/life11101084

4. Vasileva NS, Ageenko AB, Richter VA, Kuligina EV. The signaling pathways controlling the efficacy of glioblastoma therapy. Acta Naturae. 2022; 14(2): 62-70. doi: 10.32607/actanaturae.11623

5. Banijamali RS, Soleimanjahi H, Soudi S, Karimi H, Abdoli A, Seyed Khorrami SM, et al. Kinetics of oncolytic reovirus T3D replication and growth pattern in mesenchymal stem cells. Cell J. 2020; 22(3): 283-292. doi: 10.22074/cellj.2020.6686

6. O’Leary MP, Warner SG, Kim SI, Chaurasiya S, Lu J, Choi AH, et al. A novel oncolytic chimeric orthopoxvirus encoding luciferase enables real-time view of colorectal cancer cell infection. Mol Ther Oncolytics. 2018; 9: 13-21. doi: 10.1016/j.omto.2018.03.001

7. Huang Y, Wang S, Guo Q, Kessel S, Rubinoff I, Chan LL, et al. Optical coherence tomography detects necrotic regions and volumetrically quantifies multicellular tumor spheroids. Cancer Res. 2017; 77(21): 6011-6020. doi: 10.1158/0008-5472.CAN-17-0821

8. Langhans SA. Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. Front Pharmacol. 2018; 9: 6. doi: 10.3389/fphar.2018.00006

9. Xin X, Wang H, Han L, Wang M, Fang H, Hao Y, et al. Singlecell analysis of the impact of host cell heterogeneity on infection with foot-and-mouth disease virus. J Virol. 2018; 92(9): e00179-18. doi: 10.1128/JVI.00179-18

10. Novoa RR, Calderita G, Arranz R, Fontana J, Granzow H, Risco C. Virus factories: Associations of cell organelles for viral replication and morphogenesis. Biol Cell. 2005; 97(2): 147-172. doi: 10.1042/BC20040058

11. Kochneva G, Sivolobova G, Tkacheva A, Grazhdantseva A, Troitskaya O, Nushtaeva A. Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy. Oncotarget. 2016; 7(45): 74171-74188. doi: 10.18632/oncotarget.12367

12. Law AMK, Rodriguez de la Fuente L, Grundy TJ, Fang G, Valdes-Mora F, Gallego-Ortega D. Advancements in 3D cell culture systems for personalizing anti-cancer therapies. Front Oncol. 2021; 11: 782766. doi: 10.3389/fonc.2021.782766

13. Gjorevski N, Piotrowski AS, Varner VD, Nelson CM. Dynamic tensile forces drive collective cell migration through three-dimensional extracellular matrices. Sci Rep. 2015; 5: 11458. doi: 10.1038/srep11458

14. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013; 501(7467): 373-379. doi: 10.1038/nature12517

15. Ogawa J, Pao GM, Shokhirev MN, Verma IM. Glioblastoma model using human cerebral organoids. Cell Rep. 2018; 23(4): 1220-1229. doi: 10.1016/j.celrep.2018.03.105